Publication: Which Rivastigmine Formula is Better for Heart in Elderly Patients With Alzheimer-s Disease: Oral or Patch?
| dc.contributor.author | Isik, Ahmet Turan | |
| dc.contributor.author | Soysal, PINAR | |
| dc.contributor.author | YAY, Adnan | |
| dc.contributor.institutionauthor | SOYSAL, PINAR | |
| dc.date.accessioned | 2020-10-29T23:12:41Z | |
| dc.date.available | 2020-10-29T23:12:41Z | |
| dc.date.issued | 2014-12-01T00:00:00Z | |
| dc.description.abstract | Objective: Rivastigmine is commonly used for the treatment of Alzheimer-s disease (AD). All cholinesterase inhibitors, including rivastigmine, may cause cardiac side effects. The aim of this study is to compare the electrocardiographic (ECG) and hypotensive effects of formulations of rivastigmine. | |
| dc.identifier.citation | Isik A. T. , Soysal P., YAY A., -Which Rivastigmine Formula is Better for Heart in Elderly Patients With Alzheimer-s Disease: Oral or Patch?-, AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, cilt.29, ss.735-738, 2014 | |
| dc.identifier.doi | 10.1177/1533317514536598 | |
| dc.identifier.pubmed | 24867375 | |
| dc.identifier.scopus | 84911404637 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12645/26942 | |
| dc.identifier.wos | WOS:000345335300013 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.title | Which Rivastigmine Formula is Better for Heart in Elderly Patients With Alzheimer-s Disease: Oral or Patch? | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.avesis.id | d5d916d4-2497-48d4-8102-934c33751565 | |
| local.indexed.at | PubMed | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| local.publication.isinternational | 1 | |
| relation.isAuthorOfPublication | 0e36986e-d71d-4579-a395-877af097ade5 | |
| relation.isAuthorOfPublication.latestForDiscovery | 0e36986e-d71d-4579-a395-877af097ade5 |